18 May 2013
Keywords: Novartis, Ruxolitinib, Incyte, Myelofibrosis, Blood cancer
Article | 16 March 2011
Swiss drug major Novartis (NOVN: VX) revealed yesterday that it expects to file for approval in the second quarter of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 March 2011
15 March 2011
17 May 2013
© 2013 thepharmaletter.com